Emetic activity of reduced lysergamides. Johnson, F. N., Ary, I. E., Teiger, D. G., Kassel, R. J. 1973. Journal of medicinal chemistry, 16(5), 532–537. DOI: 10.1021/jm00263a028
Summary from Claude:
Looking at this document, I can provide some insight into the relationship between LSD and nausea/vomiting.
The document is a 1973 research paper investigating the emetic (vomiting-inducing) activity of lysergamides, which are chemical compounds structurally related to LSD. Here are the key findings:
Key Insights:
LSD itself has minimal emetic activity:
• The researchers tested LSD and found it required >1 mg/kg IV to induce vomiting in dogs - this is considered a very high dose with minimal emetic effect
Structurally similar compounds vary dramatically:
• Some related ergot alkaloids (ergocristine, dihydroergotoxine components) are extremely potent emetics at doses as low as 0.003-0.025 mg/kg
• The research found that 9,10-dihydrolysergamides of primary amines possess potent emetic activity comparable to ergot alkaloids
• Small structural changes dramatically affect emetic potency
Why This Matters for LSD Users:
1. Chemical purity issues: If LSD contains trace amounts of related lysergamides or ergot alkaloids as impurities from synthesis, these could cause nausea/vomiting even at very low concentrations
2. Structural sensitivity: The research shows that tiny molecular differences in this chemical family create huge differences in emetic potency - up to 300-fold differences between similar compounds
3. Individual variation: Some people may be more sensitive to either LSD itself or trace contaminants
This suggests that nausea from LSD may be related to synthesis byproducts or individual sensitivity rather than LSD's primary mechanism of action.
Great question! Let me break down what 9,10-dihydrolysergamides of primary amines means:
The Chemical Structure:
Lysergamides are a family of compounds based on lysergic acid. Think of them as chemical cousins of LSD. They all share a core structure called the "ergoline skeleton."
9,10-dihydro means:
• There's a chemical bond (a double bond) between positions 9 and 10 in the molecule
• When you add hydrogen to "reduce" this double bond, it becomes a single bond
• This is the "dihydro" part - literally "two hydrogens" added
• This small change dramatically alters the molecule's properties
Primary amines refers to:
• The "amide" part of the molecule (the tail end that sticks off lysergic acid)
• "Primary" means it's attached to a simple amine group with the formula -NH-R, where R is a simple carbon chain
• Examples from the paper: n-butylamine, isopropylamine, cyclohexylamine
The Key Finding:
The researchers discovered that only when you have:
1. The reduced 9,10 double bond (dihydro) AND
2. A simple primary amine attached
...do you get potent emetic (vomiting) activity.
What This Means Practically:
• LSD has the 9,10 double bond intact (not reduced) - so it's NOT a dihydro compound
• This is likely why LSD itself causes minimal nausea
• But if LSD is contaminated with these specific dihydro derivatives during synthesis, even tiny amounts could cause significant nausea/vomiting
The paper essentially maps out which molecular variations cause vomiting and which don't!
Great questions! Let me explain amines and then list all the specific chemicals.
What is an "Attached Amine"?
An amine is a nitrogen-containing group. Think of it as ammonia (NH₃) where you replace hydrogens with carbon chains.
"Attached" means it's bonded to the lysergic acid core structure through an amide linkage (-CONH-).
Types of amines:
• Primary: -NH₂ with one carbon chain (like -NH-CH₂CH₃)
• Secondary: nitrogen with two carbon chains
• Tertiary: nitrogen with three carbon chains
All Chemicals Named in This Report:
Parent Compounds & Standards:
1. LSD (d-lysergic acid diethylamide)
2. d-Lysergic acid (the starting material)
3. Ergocristine
4. Ergocornine
5. Ergocryptine
6. Dihydroergotoxine (mixture of three compounds below)
7. 9,10-Dihydroergocornine
8. 9,10-Dihydroergocristine
9. 9,10-Dihydroergocryptine
Lysergamides (Table I - compounds 1a-1h):
10. d-N-n-Butyllysergamide (1a)
11. d-N-tert-Butyllysergamide (1b)
12. d-N-Cyclohexyllysergamide (1c)
13. d-N,N-Di-n-butyllysergamide (1d)
14. d-N-Isopropyллysergamide (1e)
15. d-N-n-Propyllysergamide (1f)
16. d-N-(3,7-Dimethyloctyl)lysergamide (1g)
17. d-N-(1,1,3,3-Tetramethylbutyl)lysergamide (1h)
9,10-Dihydrolysergamides (Table II - compounds 2a-2i):
18. d-N-n-Butyl-9,10-dihydrolysergamide (2a)
19. d-9,10-Dihydrolysergamide (2b)
20. d-N-Cyclohexyl-9,10-dihydrolysergamide (2c)
21. d-N,N-Di-n-butyl-9,10-dihydrolysergamide (2d)
22. d-9,10-Dihydro-N-isopropyllysergamide (2e)
23. d-9,10-Dihydro-N-n-propyllysergamide (2f)
24. d-9,10-Dihydro-N-(3,7-dimethyloctyl)lysergamide (2g)
25. d-9,10-Dihydro-N-(1,1,3,3-tetramethylbutyl)lysergamide (2h)
26. d-9,10-Dihydro-N-(2-propynyl)lysergamide (2i)
2,3-Dihydrolysergamides (Table III - compounds 3a-3c):
27. d-N-n-Butyl-2,3-dihydrolysergamide (3a)
28. d-N-Cyclohexyl-2,3-dihydrolysergamide (3b)
29. d-2,3-Dihydro-N-isopropyllysergamide (3c)
Tetrahydrolysergamides (Table IV - compounds 7a-7c, 8a-8b):
30. d-N-n-Butyl-2,3,9,10-tetrahydrolysergamide (7a)
31. d-2,3,9,10-Tetrahydrolysergamide (7b)
32. d-N-Isopropyl-2,3,9,10-tetrahydrolysergamide (7c)
33. N-n-Butyl-2,3,9,10-tetrahydrolysergamide (8a) - isomer of 7a
34. 2,3,9,10-Tetrahydrolysergamide (8b) - isomer of 7b
Bromo Derivatives (Table V - compounds 9-12):
35. d-2-Bromo-N-n-butyl-9,10-dihydrolysergamide (9)
36. d-2-Bromo-9,10-dihydro-N-isopropyllysergamide (10)
37. d-2,13-Dibromo-N-n-butyl-9,10-dihydrolysergamide (11)
38. d-2,13-Dibromo-9,10-dihydro-N-isopropyllysergamide (12)
Protected Tetrahydro Derivatives (compounds 13-19):
39. d-1-Acetyl-N-n-butyl-2,3,9,10-tetrahydrolysergamide (13)
40. d-N-n-Butyl-2,3,9,10-tetrahydro-1-(2,2,2-trichloroethoxycarbonyl)lysergamide (14)
41. d-1-Acetyl-12-bromo-N-n-butyl-2,3,9,10-tetrahydrolysergamide (15)
42. d-12-Bromo-N-n-butyl-2,3,9,10-tetrahydro-1-(2,2,2-trichloroethoxycarbonyl)lysergamide (16)
43. d-12-Bromo-N-n-butyl-2,3,9,10-tetrahydrolysergamide (17)
44. d-N-n-Butyl-13-nitro-2,3,9,10-tetrahydrolysergamide (18)
45. d-13-Amino-N-n-butyl-2,3,9,10-tetrahydrolysergamide (19)
1-Substituted Derivatives (Table VI - compounds 20a-20e):
46. 9,10-Dihydro-N-isopropyl-1-methyllysergamide (20a)
47. 9,10-Dihydro-N-isopropyl-1-n-propyllysergamide (20b)
48. 9,10-Dihydro-N-isopropyl-1-methoxymethyllysergamide (20c)
49. 9,10-Dihydro-1-dimethylaminomethyl-N-isopropyllysergamide (20d)
50. 9,10-Dihydro-N-isopropyl-1-(4-ethoxycarbonyl-1-piperazinylmethyl)lysergamide (20e)
Intermediate/Byproduct:
51. Bis(4-phenyl-1-piperazinyl)phosphinic chloride (4)
Related Acids:
52. 9,10-Dihydrolysergic acid
53. d-9,10-Dihydrolysergoyl chloride hydrochloride
Total: 53 distinct chemical compounds named
The most potent emetics were compounds 2a, 2b, 2e, and 2f - all 9,10-dihydro derivatives with simple primary amines.
Excellent question! The document provides very limited information about psychoactive effects, but there are some important clues:
Direct Mentions of CNS Activity:
The paper states in the introduction:
> "As part of a study of compounds possessing high CNS activity and a high therapeutic index, we were attracted by derivatives of lysergic acid"
This tells us they were intentionally looking for compounds with central nervous system (CNS) activity - meaning psychoactive effects.
What We Can Infer:
LSD's psychoactive potency:
• LSD is extremely psychoactive at doses of 0.00001-0.0002 mg/kg in humans
• The paper shows LSD has minimal emetic activity (>1 mg/kg needed)
• This means LSD is ~5,000-100,000x more potent psychoactively than as an emetic
The dihydro compounds:
• Are potent emetics at 0.003-0.05 mg/kg
• But the paper doesn't test or report their psychoactive effects
• This is a major gap in the data!
Critical Question the Paper Doesn't Answer:
Do the 9,10-dihydro derivatives retain psychoactive properties?
This is fascinating because:
• Reducing the 9,10 double bond is a major structural change
• It dramatically increases emetic activity (up to 300x)
• But does it decrease, eliminate, or maintain psychoactive effects?
What We Know from Other Sources:
From general pharmacology of lysergamides:
• The 9,10 double bond in LSD is thought to be critical for 5-HT2A receptor binding (the main psychedelic receptor)
• Reducing it typically reduces or eliminates psychedelic activity
• This is why dihydroergotamine (used for migraines) is not psychedelic despite being similar to LSD
The Study's True Focus:
The researchers were looking for:
1. High CNS activity (psychoactive)
2. High therapeutic index (safe)
3. But ended up discovering emetic activity instead
They likely found these compounds were:
• Too nauseating to be useful therapeutically
• Possibly less psychoactive than LSD (which is why they didn't report it)
• Interesting for understanding structure-activity relationships
Quote:
Bottom Line:
The paper strongly suggests that:
• Reducing the 9,10 double bond trades psychedelic activity for emetic activity
• These compounds are probably not recreational psychedelics
• They might be contaminants in poorly synthesized LSD that cause nausea without adding to the desired effects
This would explain why some people experience nausea on LSD - they're getting small amounts of these emetic dihydro derivatives as synthesis byproducts!
|
Threaded
Previous
Index
Next
Cultivation Supplies 
Autoflowering Cannabis Seeds 
Unfolding Nature: Being in the Implicate Order 
Golden Teacher Liquid Culture For Sale
s240779 
Icyurmt 
epilectric 
[Re: 
Edit 
Reply 
AI Thread
shroomery
Osker246
1 2 3 4 5 6 all )
ph_plus
anonymous_dude
Learyfan
orizon
skareo